|1.||Chung, J G: 17 articles (05/2005 - 01/2000)|
|2.||Hung, C F: 14 articles (09/2002 - 01/2000)|
|3.||Sim, Edith: 7 articles (01/2014 - 07/2002)|
|4.||Chung, Jing-Gung: 5 articles (03/2006 - 06/2003)|
|5.||Yang, C C: 5 articles (05/2002 - 12/2001)|
|6.||Hsia, T C: 5 articles (05/2002 - 01/2001)|
|7.||Kawamura, Akane: 4 articles (01/2009 - 01/2003)|
|8.||Lin, S S: 4 articles (05/2005 - 06/2001)|
|9.||Lee, J H: 4 articles (02/2004 - 01/2000)|
|10.||Yeh, C C: 4 articles (02/2004 - 02/2000)|
|1.||Cystic Fibrosis (Mucoviscidosis)
04/01/1996 - "The heterozygous NAT1 individual is a cystic fibrosis patient with a low level of erythrocyte arylamine N-acetyltransferase type 1 activity. "
04/01/1996 - "All individuals from the cystic fibrosis and control groups were investigated for certain allelic variants of the arylamine N-acetyltransferase type 1 gene (NAT1). "
04/01/1996 - "Arylamine N-acetyltransferase type 1 activity in erythrocytes from 16 adult cystic fibrosis patients and 19 age-matched controls were compared. "
04/01/1996 - "Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients."
01/01/1995 - "Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients."
|2.||Urinary Bladder Neoplasms (Bladder Cancer)
04/01/2011 - "The arylamine N-acetyltransferase 2 (NAT2) slow acetylation phenotype is an established risk factor for urinary bladder cancer. "
01/01/2001 - "Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk."
08/01/1999 - "Arylamine N-acetyltransferase type 2 (NAT2), chromosome 8 aneuploidy, and identification of a novel NAT1 cosmid clone: an investigation in bladder cancer by interphase FISH."
12/01/2001 - "Ellagica acid inhibits arylamine N-acetyltransferase activity and DNA adduct formation in human bladder tumor cell lines (T24 and TSGH 8301)."
12/01/2001 - "Sulindac inhibited gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in T24 human bladder tumor cells."
05/01/2002 - "The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells."
07/01/2001 - "Luteolin-inhibited arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human and mouse leukemia cells."
01/01/2001 - "Tamoxifen inhibits arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human leukemia HL-60 cells."
01/01/2002 - "Effects of garlic components diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in human promyelocytic leukemia cells."
01/01/2000 - "Effects of berberine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adduct formation in human leukemia cells."
08/01/1999 - "Polymorphic arylamine N-acetyltransferase 2 (NAT2) status varies widely between individuals and ethnic groups and has been associated with susceptibility to several cancers. "
04/01/2015 - "Expression of human arylamine N-acetyltransferase I (NAT1) has been associated with various cancer subtypes and inhibition of this enzyme with small molecule inhibitors or siRNA affects cell growth and survival. "
01/01/2013 - "Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers."
05/28/2012 - "To assess the role of arylamine N-acetyltransferase (NAT)-dependent acetylation capacity in the risk for ABP-induced liver tumors, we compared 1-year liver tumor incidence following the postnatal exposure of wild-type and NAT-deficient Nat1/2(-/-) mice to ABP. "
05/01/2002 - "The effect of paclitaxel on 2-aminofluorene-DNA adducts formation and arylamine N-acetyltransferase activity and gene expression in human lung tumor cells (A549)."
|5.||Breast Neoplasms (Breast Cancer)
02/01/2008 - "Detailed analysis of published microarray studies revealed a positive correlation between overexpression of the drug metabolizing enzyme arylamine N-acetyltransferase type 1 (NAT1) and ER positivity, and increasing evidence supports a biological role for NAT1 in breast cancer progression. "
04/01/2015 - "Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines."
02/26/2010 - "Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells."
04/01/2008 - "There is increasing evidence that human arylamine N-acetyltransferase type 1 (NAT1, EC 188.8.131.52), although first identified as a homologue of a drug-metabolising enzyme, appears to be a marker in human oestrogen receptor positive breast cancer. "
01/01/2001 - "Arylamine N-acetyltransferase activities in human breast cancer tissues."
|2.||N-acetyltalosaminuronic acid (NAT)
|3.||DNA (Deoxyribonucleic Acid)
|4.||Messenger RNA (mRNA)
|6.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|9.||Ascorbic Acid (Vitamin C)